Angiotensin receptor signaling and prostate tumor growth in mice

Jem Scott-Emuakpor, Emma Allot, Stacy A. Johnson, Lauren E. Howard, Everardo Macias, Stephen J. Freedland, Susan Gurley

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

The renin-angiotensin system, through its type 1 and type 2 angiotensin receptors (AT1R and AT2R, respectively) may have a role in prostate cancer. The objective of this pilot study was to explore that potential role by determining whether the AT1R blocker, losartan, would reduce the growth of LAPC-4 prostate cancer xenografts in nude mice. We also evaluated the tumor growth effects of using angiotensin II to activate both AT1R and AT2R simultaneously. Our data showed that losartan decreased tumor volumes by 56% versus control. This decrease reached statistical significance at day 54 (p = 0.0014). By day 54, Ki67 was also reduced in the losartan group, though not significantly so (p = 0.077). Losartan had no significant effect on AT1R or AT2R expression. Despite significant increases in both AT1R and AT2R at day 29 (p = 0.043 and 0.038, respectively), the administration of angiotensin II did not result in any significant differences in tumor volumes or ki67 at any time point. These data suggest that selective activation and induction of AT2R coupled with blockade of AT1R may slow prostate cancer growth. Future larger studies are needed to confirm these results.

Original languageEnglish (US)
Pages (from-to)107-115
Number of pages9
JournalJournal of Experimental Therapeutics and Oncology
Volume11
Issue number2
StatePublished - Jan 1 2015
Externally publishedYes

Fingerprint

Angiotensin Receptors
Losartan
Prostate
Prostatic Neoplasms
Growth
Tumor Burden
Angiotensin II
Neoplasms
Angiotensin Type 2 Receptor
Angiotensin Type 1 Receptor
Renin-Angiotensin System
Heterografts
Nude Mice

Keywords

  • Angiotensin
  • AT1R
  • AT2R
  • Cancer
  • Mouse
  • Prostate
  • RAS
  • Tumor

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery
  • Cancer Research

Cite this

Scott-Emuakpor, J., Allot, E., Johnson, S. A., Howard, L. E., Macias, E., Freedland, S. J., & Gurley, S. (2015). Angiotensin receptor signaling and prostate tumor growth in mice. Journal of Experimental Therapeutics and Oncology, 11(2), 107-115.

Angiotensin receptor signaling and prostate tumor growth in mice. / Scott-Emuakpor, Jem; Allot, Emma; Johnson, Stacy A.; Howard, Lauren E.; Macias, Everardo; Freedland, Stephen J.; Gurley, Susan.

In: Journal of Experimental Therapeutics and Oncology, Vol. 11, No. 2, 01.01.2015, p. 107-115.

Research output: Contribution to journalArticle

Scott-Emuakpor, J, Allot, E, Johnson, SA, Howard, LE, Macias, E, Freedland, SJ & Gurley, S 2015, 'Angiotensin receptor signaling and prostate tumor growth in mice', Journal of Experimental Therapeutics and Oncology, vol. 11, no. 2, pp. 107-115.
Scott-Emuakpor J, Allot E, Johnson SA, Howard LE, Macias E, Freedland SJ et al. Angiotensin receptor signaling and prostate tumor growth in mice. Journal of Experimental Therapeutics and Oncology. 2015 Jan 1;11(2):107-115.
Scott-Emuakpor, Jem ; Allot, Emma ; Johnson, Stacy A. ; Howard, Lauren E. ; Macias, Everardo ; Freedland, Stephen J. ; Gurley, Susan. / Angiotensin receptor signaling and prostate tumor growth in mice. In: Journal of Experimental Therapeutics and Oncology. 2015 ; Vol. 11, No. 2. pp. 107-115.
@article{3de5734eeb89461999f064dd39320db6,
title = "Angiotensin receptor signaling and prostate tumor growth in mice",
abstract = "The renin-angiotensin system, through its type 1 and type 2 angiotensin receptors (AT1R and AT2R, respectively) may have a role in prostate cancer. The objective of this pilot study was to explore that potential role by determining whether the AT1R blocker, losartan, would reduce the growth of LAPC-4 prostate cancer xenografts in nude mice. We also evaluated the tumor growth effects of using angiotensin II to activate both AT1R and AT2R simultaneously. Our data showed that losartan decreased tumor volumes by 56{\%} versus control. This decrease reached statistical significance at day 54 (p = 0.0014). By day 54, Ki67 was also reduced in the losartan group, though not significantly so (p = 0.077). Losartan had no significant effect on AT1R or AT2R expression. Despite significant increases in both AT1R and AT2R at day 29 (p = 0.043 and 0.038, respectively), the administration of angiotensin II did not result in any significant differences in tumor volumes or ki67 at any time point. These data suggest that selective activation and induction of AT2R coupled with blockade of AT1R may slow prostate cancer growth. Future larger studies are needed to confirm these results.",
keywords = "Angiotensin, AT1R, AT2R, Cancer, Mouse, Prostate, RAS, Tumor",
author = "Jem Scott-Emuakpor and Emma Allot and Johnson, {Stacy A.} and Howard, {Lauren E.} and Everardo Macias and Freedland, {Stephen J.} and Susan Gurley",
year = "2015",
month = "1",
day = "1",
language = "English (US)",
volume = "11",
pages = "107--115",
journal = "Journal of Experimental Therapeutics and Oncology",
issn = "1359-4117",
publisher = "Old City Publishing",
number = "2",

}

TY - JOUR

T1 - Angiotensin receptor signaling and prostate tumor growth in mice

AU - Scott-Emuakpor, Jem

AU - Allot, Emma

AU - Johnson, Stacy A.

AU - Howard, Lauren E.

AU - Macias, Everardo

AU - Freedland, Stephen J.

AU - Gurley, Susan

PY - 2015/1/1

Y1 - 2015/1/1

N2 - The renin-angiotensin system, through its type 1 and type 2 angiotensin receptors (AT1R and AT2R, respectively) may have a role in prostate cancer. The objective of this pilot study was to explore that potential role by determining whether the AT1R blocker, losartan, would reduce the growth of LAPC-4 prostate cancer xenografts in nude mice. We also evaluated the tumor growth effects of using angiotensin II to activate both AT1R and AT2R simultaneously. Our data showed that losartan decreased tumor volumes by 56% versus control. This decrease reached statistical significance at day 54 (p = 0.0014). By day 54, Ki67 was also reduced in the losartan group, though not significantly so (p = 0.077). Losartan had no significant effect on AT1R or AT2R expression. Despite significant increases in both AT1R and AT2R at day 29 (p = 0.043 and 0.038, respectively), the administration of angiotensin II did not result in any significant differences in tumor volumes or ki67 at any time point. These data suggest that selective activation and induction of AT2R coupled with blockade of AT1R may slow prostate cancer growth. Future larger studies are needed to confirm these results.

AB - The renin-angiotensin system, through its type 1 and type 2 angiotensin receptors (AT1R and AT2R, respectively) may have a role in prostate cancer. The objective of this pilot study was to explore that potential role by determining whether the AT1R blocker, losartan, would reduce the growth of LAPC-4 prostate cancer xenografts in nude mice. We also evaluated the tumor growth effects of using angiotensin II to activate both AT1R and AT2R simultaneously. Our data showed that losartan decreased tumor volumes by 56% versus control. This decrease reached statistical significance at day 54 (p = 0.0014). By day 54, Ki67 was also reduced in the losartan group, though not significantly so (p = 0.077). Losartan had no significant effect on AT1R or AT2R expression. Despite significant increases in both AT1R and AT2R at day 29 (p = 0.043 and 0.038, respectively), the administration of angiotensin II did not result in any significant differences in tumor volumes or ki67 at any time point. These data suggest that selective activation and induction of AT2R coupled with blockade of AT1R may slow prostate cancer growth. Future larger studies are needed to confirm these results.

KW - Angiotensin

KW - AT1R

KW - AT2R

KW - Cancer

KW - Mouse

KW - Prostate

KW - RAS

KW - Tumor

UR - http://www.scopus.com/inward/record.url?scp=84948406749&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84948406749&partnerID=8YFLogxK

M3 - Article

C2 - 28976133

AN - SCOPUS:84948406749

VL - 11

SP - 107

EP - 115

JO - Journal of Experimental Therapeutics and Oncology

JF - Journal of Experimental Therapeutics and Oncology

SN - 1359-4117

IS - 2

ER -